Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
藥劑科實習生:黃中成指導老師:蘇蜂琪藥師
2014.08.13
Osteoporosis
Outline
Epidemiology
Definitions
Classification
Other risk factors Associated With Development of Osteoporosis Classification
Clinical Presentation
Diagnosis
Bone remodeling model
Pharmacologic Therapy
Non-pharmacologic therapy
Conclusion
EpidemiologyThe rapid increase in the global population of osteoporosis
http://bone.la-dy.net/wiki/img_auth.php/6/68/072506.jpg
Definitions★
Osteoporosis is a bone disorder characterized by
low bone density , impaired bone architecture, and compromised bone strength predisposing a person to increased fracture risk.
Normal Osteoporosis
Classification★Primary Osteoporosis:․Postmenopausal Osteoporosis:
Estrogen deficiency during menopause increasesactivation of new osteoclasts to lose bone mass .
․Age-Related Osteoporosis:
Because of PTH , calcium , and vitamin D deficiencies leading to accelerated bone turnover andreduced osteoblast formation.
Classification★Secondary Causes of Osteoporosis:‧Cushing syndrome
‧Hyperthyroidism
‧Primary hyperparathyroidism
‧Gastrointestinal disease
‧Drugs:․corticosteroids
․long-term anticonvulsant therapy
․Loop diuretics
Other risk factors Associated With development of Osteoporosis‧Asian
‧Small stature or Low Weight
‧Excessive alcohol intake or Cigarette smoking
‧ Early menopause or oophorectomy
Clinical Presentation
Fracture(Spine、Hip、Wrist or Colles’ )
Back pain
Low activity
Kyphosis or Lordosis
Decrease height
Spine
Hip
Wrist or Colles’
Diagnosis
A WHO working group defined osteoporosis as the presence of bone mineral density(BMD) or a T-score.
Measurement of central(hip and spine)BMD with dual-energy X-ray absorptiometry(DXA) is the gold standard for osteoporosis diagnosis.
DiagnosisT-score(SD)
Bone density
Normal Bone Mass
Osteopenia
Osteoporosis
Bone remodeling model
‧Stimulating factor:‧PTH(intermittent)‧1,25(OH)2D3‧ T3 / T4‧TGF-β
‧Inhibiting factor:‧Glucocorticoid
teriparatide
Inhibiting factor:PTH(continuous)
EstogenRaloxifen
e
DenosumabBisphosphates
strontiu m
ranelate
Calcitonin
TGF-β
Cathepsin Kinhibitor
Osteoprotegerin(OPG)
1,25(OH)2D3High dose
Antiresorptive agents
Anabolic agents
Pharmacologic therapy★Bisphosphonates:
Bisphosphonateshydroxyapatite
Osteoclast
combination
Apoptosis
Pharmacological mechanism of Bisphosphonates
http://en.wikipedia.org/wiki/File:BisphosStruct.svg
Alendronate Risedronate Ibandronate Zoledronic acid Dosing 70mg Orally
once weekly150mg Orally once monthly
3mg IV infused over no less than 15 minutes. (once every 3 months)
5mg IV infused over no less than 15 minutes. (once every 12 months)
AdverseEffects
‧Esophagitis‧ONJ‧musculoskeletal
pain
‧Esophagitis‧ONJ‧musculoskeletal
pain
‧headache ‧arthralgiamusculoskeletal pain
‧Fevers ‧flulike‧symptoms ‧headache ‧arthralgia ‧musculoskeletal
pain
Pharmacologic therapySERMs:
Raloxifene
RANKL inhibitor :
Denosumab
PTH:
teriparatidestrontium ranelate
Dosing 60 mg orally once daily
60 mg subcutaneous once every 6 months
20 mcg subcutaneously once daily for up to 2 years.
2 gm Granules orally once daily
Adverse Effects ‧venous thromboembolic disease(VTE)
‧ONJ‧serum Ca ↓‧Back pain
‧Dizzy ‧Cramp ‧Diarrhea
‧Headache ‧vomiting ‧Diarrhea ‧GI disease ‧VTE‧DRESS,SJS,TEN
Contraindications Congestive heart failure
Low serum Ca Osteosarcoma:‧Paget bone
disease ‧unexplained
alkalinephosphataseelevations
‧open epiphyses
‧transient ischemic attacks‧Antacid with
cation ion ‧tetracycline ‧quinolone
Therapy of osteoporosis in men:Drugs Form of Drugs
Alendronate(Fosamax®)
Oral(tablet)Oral(liquid solution)
Alendronate(Fosamax® Plus Vit D)
Oral(tablet)
Risedronate(Actonel®)
Oral(tablet)
Parathyroid Hormone(teriparatide / Ferteo®)
Injection(IM‚SC)
strontium ranelate(Protos®)
Oral
Therapy of Postmenopausal Osteoporosis:Drugs Form of Drug
Alendronate(Fosamax®)
Oral(tablet)Oral(liquid solution)
Alendronate(Fosamax® Plus Vit D) Oral(tablet)Ibandronate(Boniva®)
Oral(tablet)Intravenous(IV)
Risedronate(Actonel®)
Oral(tablet)
Zoledronic acid(Reclast®,Taiwan called Aclasta®)
Intravenous(IV)
SERMsRaloxifene(Evista®) Oral(tablet)
Human monoclonal antibody for RANKL:
Denosumab(Prolia®)
Injection(SC)
Parathyroid Hormone(teriparatide / Ferteo®)
strontium ranelate(Protos®)
Injection(IM‚SC)
Oral
Non-pharmacologic therapy: Vitamin D 、PTH and Calcium
PTH
25-hydroxyvitamine D
1,25-dihydroxyvitamine D
Ca resorption
Decrease resorption of P
TH
Ca resorption
Glucocorticoids
Increase excretion of Ca
Blood —Low CalciumConcentration
Calciumfor Resorption
Conclusion:★目前骨質疏鬆症治療的首選藥為雙磷酸鹽類,尤以口服劑
型為優先。至於藥物合併使用方面,一般不建議併用二種抗 溶蝕藥品,如雙磷酸鹽類加Raloxifene的治療,因其會過度
抑制骨骼汰舊率,導致骨骼太脆。而Alendronte合併 teriparatide對骨質密度無好處,且會降低teriparatide的同化
效果。★想要維持良好的骨健康,從年輕時期就應養成良好生活型
態,避免煙、酒和過量咖啡,均衡營養和規律運動,並多補 充鈣質,儲存骨本,使身體有較高的「尖峰骨量」。
★中年時期更須加強保護骨本,更年期婦女應儘早評估是否 宜補充女性荷爾蒙預防骨流失;年老時期則須加強防跌以防
範生骨折。
Reference
MICROMEDEX
APPLIED THERAPEUYICS TENTH EDITION
藥學雜誌 119版 69-74 骨質疏鬆症的治療
Airiti 骨質疏鬆症的藥物治療
行政院衛生署國民健康局-骨質疏鬆症-臨床治療指引
臺安醫院
醫藥專欄
http://mypaper.pchome.com.tw/an8100shaow/post/13253484 07
http://www.nhsdirect.wales.nhs.uk/encyclopaedia/c/article/co rticosteroid(drugs)
http://www.scoopthelake.com/2014/04/29/risk-factors- osteoporosis-women/
http://www.ultimatechirocare.com/cat-news-healthcare- naperville-woodridge-lisle-illinois-il/what-are-the-symptoms- of-osteoporosis/
http://healthyliving88.com/osteoporosis/treatment-care/
http://mypaper.pchome.com.tw/an8100shaow/post/1325348407http://mypaper.pchome.com.tw/an8100shaow/post/1325348407http://www.nhsdirect.wales.nhs.uk/encyclopaedia/c/article/corticosteroid(drugs)http://www.nhsdirect.wales.nhs.uk/encyclopaedia/c/article/corticosteroid(drugs)http://www.scoopthelake.com/2014/04/29/risk-factors-osteoporosis-women/http://www.scoopthelake.com/2014/04/29/risk-factors-osteoporosis-women/http://www.ultimatechirocare.com/cat-news-healthcare-naperville-woodridge-lisle-illinois-il/what-are-the-symptoms-of-osteoporosis/http://www.ultimatechirocare.com/cat-news-healthcare-naperville-woodridge-lisle-illinois-il/what-are-the-symptoms-of-osteoporosis/http://www.ultimatechirocare.com/cat-news-healthcare-naperville-woodridge-lisle-illinois-il/what-are-the-symptoms-of-osteoporosis/
OsteoporosisOutline�Epidemiology�DefinitionsClassificationClassificationOther risk factors Associated With development of OsteoporosisClinical PresentationDiagnosisDiagnosis�Bone remodeling model投影片編號 12Pharmacologic therapy投影片編號 14Pharmacologic therapyTherapy of osteoporosis in men:Therapy of Postmenopausal Osteoporosis:Non-pharmacologic therapy:�Vitamin D 、PTH and CalciumConclusion:Reference投影片編號 21